vidarabine has been researched along with Hyperplasia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Guo, N; Liu, Y; Lou, B; Tian, Y; Wu, Y; You, H; Yuan, Z; Zhang, Y; Zhao, Q; Zhou, D; Zhou, J | 1 |
| Cavaliere, AL; Coppola, C; Curcio, A; De Serio, D; Ellison, GM; Galuppo, V; Gasparri, C; Indolfi, C; Leone, A; Surace, FC; Torella, D | 1 |
2 other study(ies) available for vidarabine and Hyperplasia
| Article | Year |
|---|---|
IFN-γ aggravates neointimal hyperplasia by inducing endoplasmic reticulum stress and apoptosis in macrophages by promoting ubiquitin-dependent liver X receptor-α degradation.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Apolipoproteins E; Apoptosis; Endoplasmic Reticulum Stress; Hyperplasia; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Interferon-gamma; Liver X Receptors; Macrophages; Male; Mice; Mice, Knockout; Neointima; Protein Inhibitors of Activated STAT; Ubiquitin; Ubiquitination; Vidarabine | 2017 |
Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.
Topics: Angioplasty, Balloon; Animals; Aorta; Cardiovascular Agents; Carotid Artery Injuries; Carotid Stenosis; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Feasibility Studies; Hyperplasia; Janus Kinase 2; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Prosthesis Design; Rabbits; Rats; Rats, Wistar; RNA, Antisense; STAT1 Transcription Factor; Stents; Time Factors; Transfection; Tunica Intima; Vidarabine | 2007 |